Detail akcie Alzamend Rg online

Business Summary: Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
Financial Summary: BRIEF: For the six months ended 31 October 2025, Alzamend Neuro Inc revenues was not reported. Net loss applicable to common stockholders increased 55% to $3.7M. Higher net loss reflects Research and development increase from $518K to $1.9M (expense), General and administrative - Bal increase of 14% to $1.1M (expense), Other SGA increase of 28% to $187K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$14.88 to -$1.58.